A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- 08 May 2019 Status changed from recruiting to discontinued.
- 21 Aug 2018 Status changed from not yet recruiting to recruiting.
- 05 Apr 2018 New trial record